• Radiofrequency Ablation Provides Fast Relief of Painful Bone Tumors

  NEW YORK (Reuters Health) - Radiofrequency ablation (RFA) for the palliative treatment of patients whose cancer has spread to the bone provides rapid and sustained pain relief and improves quality of

  2021-03-08

• Adherence to Antireflux Lifestyle Factors Shows Benefit in Women

  Antireflux lifestyle factors may significantly reduce the risk of gastroesophageal reflux disease (GERD), according to an analysis involving almost 43,000 women.Even alongside therapy with a

  2021-03-01

• EU Panel Backs Icosapent Ethyl for CV Event Reduction

  The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of icosapent ethyl to reduce the risk for cardiovascular (CV) events in pat

  2021-02-20

• PICaSSO Tool Promising for Predicting Histologic Remission in Ulcerative Colitis

  NEW YORK (Reuters Health) - The recently developed Paddington International Virtual ChromoendoScopy ScOre (PICaSSO) accurately identified both endoscopic and histologic remission in ulcerative colitis

  2021-02-12

• Invasive Tests Prompted by Cancer Screening Show High Real-World Complication Rate

  NEW YORK (Reuters Health) - In real-world circumstances, procedures such as biopsy indicated by lung-cancer screening with low-dose computed tomography (LDCT) may not go quite as smoothly as indicated

  2021-01-20

• ACC/AHA Valvular Heart Disease Update Backs Less-Invasive Approach

  The latest iteration of the American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Management of Patients With Valvular Heart Disease emphasizes a less invasive approach

  2021-01-02

• FDA Approves Shorter Infusion Time for MS Drug Ocrelizumab

  The US Food and Drug Administration (FDA) has approved a shorter infusion time for ocrelizumab (Ocrevus) for patients with relapsing or primary progressive multiple sclerosis (MS),

  2020-12-15

• Adding Atezolizumab to Chemo Doesn't Worsen QOL in Early TNBC

  Adding the immune checkpoint inhibitor atezolizumab to first-line therapy for early triple-negative breast cancer (TNBC) did not significantly worsen patients' quality of life, according to new da

  2020-12-14